CDH1致病性变异者全胃切除术最佳时机模拟研究
该研究用马尔可夫模型模拟CDH1致病性变异者不同年龄行预防性全胃切除术(PTG)的结局,以质量调整生命年(QALYs)为主要终点,发现男性最佳PTG年龄为39岁、女性为30岁,均晚于现行指南推荐的20-30岁。
要点
- 男性PTG最佳年龄39岁,增量QALYs 32.01,终生癌症死亡率8.5%。
- 女性PTG最佳年龄30岁,增量QALYs 33.09,终生癌症死亡率1.6%。
- PTG前内镜监测可降低男性癌症死亡率至6.7%,但QALYs较低(31.59)。
核心结论
- 以QALYs为主要终点时,男性最佳PTG年龄为39岁,女性为30岁,均晚于现行推荐。
研究设计与样本
- 采用马尔可夫模型模拟CDH1致病性变异相关的遗传性弥漫性胃癌(HDGC)进展,模拟不同PTG年龄(20-79岁)的假设队列。
- 模型输入包括健康状态转移概率、死亡与并发症率、生活质量效用值及内镜监测敏感性,均源自已发表文献。
主要发现
- 男性39岁行PTG获32.01增量QALYs、58.81生命年(生物学年龄72.81岁),终生癌症死亡率8.5%。
- 男性PTG前内镜监测使癌症死亡率降至6.7%,但QALYs较低(31.59)。
- 男性30岁行PTG使癌症死亡率降至3.2%,增量QALYs 31.45。
- 女性30岁行PTG获33.09增量QALYs、66.17生命年(生物学年龄80.17岁),终生癌症死亡率1.6%。
- 女性PTG前加内镜监测未降低HDGC死亡风险。
临床怎么用
- 模型模拟结果提示,以QALYs为主要终点时,男性PTG最佳年龄为39岁、女性为30岁。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Carriers of pathogenic variants in CDH1 have a high risk of hereditary diffuse gastric cancer (HDGC). Guidelines recommend prophylactic total gastrectomy (PTG) at age 20-30 years, although there is controversy over the optimal age. We developed a simulation model to analyze the effects of PTG at different ages on quality-adjusted life-years (QALYs), cancer mortality, and life expectancy. METHODS: We used a Markov model of HDGC progression associated with pathogenic variants in CDH1 to simulate outcomes of hypothetical cohorts with different ages at time of PTG (ages 20-79 years). Model inputs including health state transition probabilities, mortality and complication rates, quality of life utility values, and endoscopic surveillance sensitivity were derived from publications. The primary outcome, used to determine the optimal strategy, was age at which PTG yielded the highest QALYs. Secondary outcomes were cancer mortality and unadjusted life-years. RESULTS: Our model found that for men, the optimal age for PTG is 39 years, resulting in 32.01 incremental QALYs, 58.81 life-years (biologic age, 72.81 years), and lifetime cancer mortality of 8.5%. Incorporating endoscopic surveillance prior to PTG decreased cancer mortality to 6.7%, but had lower QALYs (31.59). PTG at age 30 reduced cancer mortality to 3.2%, with 31.45 incremental QALYs. For women, the optimal age for PTG was calculated to be 30 years, with 33.09 incremental QALYs, 66.17 life-years (biologic age, 80.17 years), and lifetime cancer mortality of 1.6%. Addition of endoscopic surveillance did not decrease the risk of HDGC mortality in women. CONCLUSIONS: Using a Markov model of HDGC progression associated with pathogenic variants in CDH1 to simulate outcomes, we found the optimal ages for PTG to be 39 years for men and 30 years for women, when QALYs are the primary endpoint. These ages for PTG are older than those of current recommendations.
引用
- Laszkowska M, Silver ER, Schrope B, et al. Optimal Timing of Total Gastrectomy to Prevent Diffuse Gastric Cancer in Individuals With Pathogenic Variants in CDH1. Clin Gastroenterol Hepatol. 2019. PMID: 31220641. doi:10.1016/j.cgh.2019.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。